RFS was only reported in five studies and the combined HR was 2.46 (95% CI 1.87–3.24, p < 0.0001), which indicated that SATB1 overexpression is associated with 2.46 fold increased risk of cancer relapse in gastrointestinal tract cancer (Figure 2B). This evidence concerns the gene SATB1 and digestive system cancer.